Molecular markers to individualize adjuvant therapy for colon cancer

Nature Reviews Clinical Oncology

Volumn 7, Issue 6, 2010, Pages 318-325

  Gangadhar, Tara ^a   Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAPECITABINE; CYCLOOXYGENASE 2; EDRECOLOMAB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GUANYLATE CYCLASE; GUANYLATE CYCLASE 2; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PROTEIN P53; SMAD4 PROTEIN; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; PLATINUM COMPLEX;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 18Q; CLINICAL TRIAL; COLON ADENOMA; COLON CANCER; COLON CARCINOMA; DECISION SUPPORT SYSTEM; DRUG EFFICACY; GENE MUTATION; HETEROZYGOSITY; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE K RAS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; COLONIC NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS;

EID: 77953587132     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.62     Document Type: Review

References (71)

1. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
3. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
4. Kabbinavar, F. F. et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 23, 3706-3712 (2005).
5. Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013-2019 (2008).
6. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
7. Laurie, J. A. et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J. Clin. Oncol. 7, 1447-1456 (1989).
8. Moertel, C. G. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352-358 (1990).
9. Moertel, C. G. et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 122, 321-326 (1995).
10. Advanced Colorectal Cancer Meta-Analysis Project investigators. Modulation of fluorouracil by leukovorin in patients with advanced colorectal cancer. J. Clin. Oncol. 10, 896-903 (1992).
11. Wolmark, N. et al. The benefit of leucovorinmodulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol. 11, 1879-1887 (1993).
12. Wolmark, N. et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. 17, 3553-3559 (1999).
13. Haller, D. G. et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J. Clin. Oncol. 23, 8671-8678 (2005).
14. Douillard, J. Y. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 355, 1041-1047 (2000).
15. Saltz, L. B. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905-914 (2000).
16. de Gramont, A. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000).
17. André, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109-3116 (2009).
18. André, T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343-2351 (2004).
19. Kuebler, J. P. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol. 25, 2198-2204 (2007).
20. Haller, D. G. et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FULV for stage III colon cancer (NO16968): No impact of age on disease free survival (DFS). Gastrointestinal Cancers Symp. Abstract 284 (2010).
21. Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/ leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117-3125 (2009).
22. Saltz, L. B. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25, 3456-3461 (2007).
23. Quasar collaborative group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370, 2020-2029 (2007).
24. International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J. Clin. Oncol. 17, 1356-1363 (1999).
25. Gill, S. et al. Pooled analysis of fluorouracilbased adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol. 22, 1797 - 1806 (2004).
26. O'Connell, J. B., Maggard, M. A. & Ko, C. Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 96, 1420-1425 (2004).
27. National Comprehensive Cancer Network. NCCP clinical practice guidelines in oncology [online] http://www.nccn.org/professionals/ physician-gls/f- guidelines.asp.
28. O'Connell, M. J. et al. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J. Clin. Oncol. 26, 2336-2341 (2008).
29. Gianni, L. et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23, 7265-7277 (2005).
30. Habel, L. A. et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8, R25 (2006).
31. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
32. Aaltonen, L. A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812-816 (1993).
33. Thibodeau, S. N., Bren, G. & Schaid, D. Microsatellite instability in cancer of the proximal colon. Science 260, 816-819 (1993).
34. Markowitz, S. D. & Bertagnolli, M. M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449-2460 (2009).
35. Herman, J. G. et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA 95, 6870-6875 (1998).
36. Lindor, N. M. et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol. 20, 1043-1048 (2002).
37. Ribic, C. M. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247-257 (2003).
38. Tejpar, S. et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J. Clin. Oncol. (Meeting abstracts) 27, 4001 (2009).
39. Sargent, D. J. et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J. Clin. Oncol. (Meeting abstracts) 29, 4008 (2008).
40. Bertagnolli, M. M. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 27, 1814-1821 (2009).
41. Collacchio, T. A. et al. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). J. Clin. Oncol. (Meeting abstracts) 22, 3522 (2004).
42. Boland, C. R. et al. A National Cancer Institute workshop on microsatellite instabiity for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248-5257 (1998).
43. Roth, A. et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J. Clin. Oncol. (Meeting abstracts) 27, 4002 (2009).
44. Baker, S. J. et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217-221 (1989).
45. Fearon, E. R. et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247, 49-56 (1990).
46. Thiagalingam, S. et al. Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 13, 343-346 (1996).
47. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
48. Jen, J. et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J. Med. 331, 213-221 (1994).
49. Ogunbiyi, O. A. et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J. Clin. Oncol. 16, 427-433 (1998).
50. Popat, S. & Houlston, R. S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur. J. Cancer 41, 2060-2070 (2005).
51. Ogino, S. et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J. Clin. Oncol. 27, 4591-4598 (2009).
52. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ ct/show/NCT00217737 (2010).
53. Watanabe, T. et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344, 1196-1206 (2001).
54. de Gramont, A. et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J. Clin. Oncol. (Meeting abstracts) 26, 4007 (2007).
55. Wolmark, N. et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J. Clin. Oncol. (Meeting abstracts) 27, LBA4 (2009).
56. Ogino, S. et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res. 15, 7322-7329 (2009).
57. Westra, J. L. et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J. Clin. Oncol. 23, 5635-5643 (2005).
58. Pitari, G. M. et al. The paracrine hormone hypothesis of colorectal cancer. Clin. Pharmacol. Ther. 82, 441-447 (2007).
59. Waldman, S. A. et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 301, 745-752 (2009).
60. Resnick, M. B., Routhier, J., Konkin, T., Sabo, E. & Pricolo, V. E. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin. Cancer Res. 10, 3069-3075 (2004).
61. Mulder, J. W., Baas, I. O., Polak, M. M., Goodman, S. N. & Offerhaus, G. J. Evaluation of p53 protein expression as a marker for longterm prognosis in colorectal carcinoma. Br. J. Cancer 71, 1257-1262 (1995).
62. Adrover, E. et al. Expression of high p53 levels in colorectal cancer: a favorable prognostic factor. Br. J. Cancer 81, 122-126 (1999).
63. Lenz, H. J. et al. ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONFIRM2. J. Clin. Oncol. (Meeting abstracts) 26, 4131 (2008).
64. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/ NCT00846482 (2009).
65. Kerr, D. et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J. Clin. Oncol. (Meeting abstracts) 27, 4000 (2009).
66. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct/show/ NCT00079274 (2009).
67. Cancer and Leukemia Group B summer group meeting agenda. calgb.org [online], http:// www.calgb.org/Public/meetings/ meeting-documents/2009/summer- group/ AgendaBook-062,009.pdf (2009).
68. Soumaoro, L. T. et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin. Cancer Res. 10, 8465-8471 (2004).
69. Dubé, C. et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann. Intern. Med. 146, 365-375 (2007).
70. Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302, 649-658 (2009).
71. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct/show/ NCT00112918 (2009).